ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

JNJ Johnson and Johnson

144.59
0.00 (0.00%)
01 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Johnson and Johnson NYSE:JNJ NYSE Common Stock
  Price Change % Change Share Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 144.59 0 01:00:00

NY Files Charges Against J&J Over Opioids -- Update

17/09/2020 5:40pm

Dow Jones News


Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Johnson and Johnson Charts.
   By Stephen Nakrosis 
 

New York State Gov. Andrew Cuomo Thursday said the state has filed charges against Johnson & Johnson and several of its subsidiaries, alleging the company fraudulently mischaracterized the safety and effectiveness of opioid drugs in an effort to expand the market.

The actions are a part of an effort to recover $2 billion in insurance premium overcharges for New York residents, the state's Department of Financial Services said in a release.

The department said it has initiated administrative proceedings against J&J and its subsidiaries Janssen Pharmaceutica, Janssen Pharmaceuticals, and Ortho-McNeil-Janssen Pharmaceuticals.

The claim alleges that J&J has "had a long-standing and multi-faceted leading role in originating, supplying, facilitating, and actively creating a dangerous market for opioids for chronic pain treatment."

The department alleges J&J violated parts of the state's insurance law, and that each fraudulent prescription constitutes a separate violation.

J&J said in a statement that its marketing and promotion of prescription opioid pain medications was "appropriate and responsible."

"Janssen provided these medicines for doctors treating patients suffering from pain and worked with regulators to provide appropriate information about their risks and benefits--everything you'd expect a responsible company to do," the company said.

A hearing is scheduled for Jan. 25.

 

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

 

(END) Dow Jones Newswires

September 17, 2020 12:25 ET (16:25 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

1 Year Johnson and Johnson Chart

1 Year Johnson and Johnson Chart

1 Month Johnson and Johnson Chart

1 Month Johnson and Johnson Chart

Your Recent History

Delayed Upgrade Clock